Evidence map›Paper›PMID 39840134›Full record

ArticleFrontiers in bioengineering and biotechnology2024

Biomimetic bioreactor for potentiated uricase replacement therapy in hyperuricemia and gout.

Bin Yang, Guihu Luo, Tailei Nie, Zhenglan Ban, Quanxin Ning, Jialin Zhang, Xiangru Liu, Yanhua Lin, Xiaochun Xie, Qianyun Chen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bin Yang *Department of Rheumatology and Immunology, The Third Affiliated Hospital of Southern Medical University, Institute of Clinical Immunology, Academy of Orthopedics, Guangzhou, Guangdong, China.
Guihu Luo *Department of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Tailei NieDepartment of Pharmacy, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Zhenglan BanNational Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, China.
Quanxin NingNational Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, China.
Jialin ZhangDepartment of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Xiangru LiuXingtan Hospital Affiliated of Southern Medical University Shunde Hospital, Foshan, China.
Yanhua LinDepartment of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Xiaochun XieSchool of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Qianyun ChenDepartment of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Han ZhongDepartment of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Ying HuangDepartment of Rheumatology and Immunology, Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde), Foshan, China.
Pan LiaoDepartment of Rheumatology and Immunology, Hunan University of Medicine General Hospital, HuaiHua, China.
Yan LiuNational Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, China.
Chenyang GuoNational Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, China.
Chuanxu ChengNational Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, Guangdong, China.
Erwei SunDepartment of Rheumatology and Immunology, The Third Affiliated Hospital of Southern Medical University, Institute of Clinical Immunology, Academy of Orthopedics, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Uricase replacement therapy is a promising approach for managing hyperuricemia and gout but is hindered by challenges such as short blood circulation time, reduced catalytic activity, and excessive hydrogen peroxide (H Methods: We designed and synthesized RBC@SeMSN@Uri, a red blood cell-coated biomimetic self-cascade bioreactor, which encapsulates uricase (Uri) and a selenium-based nano-scavenger (SeMSN) within RBC membranes. This design aims to reduce immunogenicity, extend systemic circulation, and maintain enzymatic activity. Results: RBC@SeMSN@Uri effectively degraded uric acid (UA) into allantoin and converted H Discussion: This study presents RBC@SeMSN@Uri as a novel biomimetic strategy for enzyme replacement therapy in hyperuricemia and gout. By integrating uricase and selenium-based nano-scavenger within RBC membranes, the bioreactor addresses key limitations of traditional therapies, offering enhanced stability, reduced immunogenicity, and superior therapeutic efficacy. This platform holds potential for broader applications in protein or antibody delivery for enzyme replacement therapies in other diseases.

Indexed as

biomimetic bioreactorgouthyperuricemiared blood cell coatingselenium-based nanoscavengeruricase

Identifiers

PMID39840134
PMCPMC11746906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.